Retirement Systems of Alabama Cuts Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Retirement Systems of Alabama cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,333 shares of the medical research company’s stock after selling 495 shares during the period. Retirement Systems of Alabama’s holdings in IQVIA were worth $7,336,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. E. Ohman J or Asset Management AB boosted its stake in IQVIA by 12.1% in the fourth quarter. E. Ohman J or Asset Management AB now owns 8,361 shares of the medical research company’s stock valued at $1,643,000 after acquiring an additional 900 shares during the last quarter. GDS Wealth Management increased its position in IQVIA by 8.4% in the fourth quarter. GDS Wealth Management now owns 59,529 shares of the medical research company’s stock worth $11,698,000 after buying an additional 4,636 shares during the last quarter. Oregon Pacific Wealth Management LLC bought a new stake in shares of IQVIA in the fourth quarter valued at $470,000. Magnolia Capital Advisors LLC lifted its position in shares of IQVIA by 2.9% during the 4th quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company’s stock valued at $516,000 after buying an additional 74 shares during the last quarter. Finally, Western Pacific Wealth Management LP grew its stake in shares of IQVIA by 44.4% during the 4th quarter. Western Pacific Wealth Management LP now owns 845 shares of the medical research company’s stock worth $166,000 after acquiring an additional 260 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by insiders.

IQVIA Stock Performance

NYSE IQV opened at $208.13 on Monday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a fifty day moving average of $200.67 and a 200-day moving average of $219.40. The company has a market capitalization of $37.78 billion, a P/E ratio of 27.75, a P/E/G ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Stephens initiated coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price on the stock. Stifel Nicolaus reduced their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $252.39.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.